Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.42 |
| ▸ | PRKG1 | Q13976 | 8/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 3/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 2/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956455 | 0.82 | ROCK2 (0.37) | ROCK2PRKG1CYP1A2LIMK2EHMT2 | |
| SCHEMBL7956390 | 0.78 | PIM1 (0.42) | ROCK2PRKG1CYP1A2LIMK2PIM1 | |
| SCHEMBL20755270 | 0.77 | GAA (0.46) | ROCK2PRKG1EHMT2 | |
| SCHEMBL7947501 | 0.75 | LIPG (0.61) | — | |
| SCHEMBL31480867 | 0.74 | ALDH1A1 (0.48) | ACACB | |
| SCHEMBL15783909 | 0.74 | MAPT (0.52) | ATR | |
| SCHEMBL30149942 | 0.74 | NOTUM (0.42) | EHMT2ACACB | |
| SCHEMBL20756736 | 0.74 | ROCK2 (0.42) | ROCK2PRKG1CYP1A2LIMK2EHMT2 | |
| SCHEMBL15676577 | 0.74 | NOTUM (0.42) | EHMT2ACACB | |
| SCHEMBL785590 | 0.74 | ROCK2 (0.51) | ROCK2PRKG1EHMT2ATRPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081903-B1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-8093250-B2 | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-2081903-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008044217-A2 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | P2RY12, P2RY2, P2RY1 | ROCK2 2742/4885PRKG1 874/4885CYP1A2 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.